28 Nov 2024 • In a phase 3 trial, participants receiving twice-yearly lenacapavir (LEN) had a significantly lower incidence of HIV infection compared to those receiving daily oral emtricitabine–tenofovir disoproxil fumarate (F/TDF).

Among 3265 participants, 2 infections occurred in the lenacapavir group (0.10 per 100 person-years), compared to 9 infections in the F/TDF group (0.93 per 100 person-years).

The background HIV incidence in the screened population was 2.37 per 100 person-years.

Lenacapavir demonstrated a lower HIV incidence than both the background incidence and the F/TDF group.

The study found no major safety concerns, though 1.2% of participants in the lenacapavir group experienced injection-site reactions, compared to 0.3% in the F/TDF group.

The results concluded that lenacapavir, administered every 26 weeks, was significantly more effective in reducing HIV risk than F/TDF, highlighting its potential as a long-term prevention option.

Source: The New England Journal of Medicine Read full story